Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial (vol 399, pg 1779, 2022)

被引:0
|
作者
Delany-Moretlwe, S.
Hughes, J. P.
Bock, P.
机构
来源
LANCET | 2022年 / 399卷 / 10337期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1778 / 1778
页数:1
相关论文
共 50 条
  • [1] Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
    Delany-Moretlwe, Sinead
    Hughes, James P.
    Bock, Peter
    Ouma, Samuel Gurrion
    Hunidzarira, Portia
    Kalonji, Dishiki
    Kayange, Noel
    Makhema, Joseph
    Mandima, Patricia
    Mathew, Carrie
    Spooner, Elizabeth
    Mpendo, Juliet
    Mukwekwerere, Pamela
    Mgodi, Nyaradzo
    Ntege, Patricia Nahirya
    Nair, Gonasagrie
    Nakabiito, Clemensia
    Nuwagaba-Biribonwoha, Harriet
    Panchia, Ravindre
    Singh, Nishanta
    Siziba, Bekezela
    Farrior, Jennifer
    Rose, Scott
    Anderson, Peter L.
    Eshleman, Susan H.
    Marzinke, Mark A.
    Hendrix, Craig W.
    Beigel-Orme, Stephanie
    Hosek, Sybil
    Tolley, Elizabeth
    Sista, Nirupama
    Adeyeye, Adeola
    Rooney, James F.
    Rinehart, Alex
    Spreen, William R.
    Smith, Kimberly
    Hanscom, Brett
    Cohen, Myron S.
    Hosseinipour, Mina C.
    [J]. LANCET, 2022, 399 (10337): : 1779 - 1789
  • [2] Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial (vol 14, pg 281, 2014)
    Grinsztejn, B.
    Hosseinipour, M. C.
    Ribaudo, H. J.
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (04): : 269 - 269
  • [3] Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
    Grinsztejn, Beatriz
    Hosseinipour, Mina C.
    Ribaudo, Heather J.
    Swindells, Susan
    Eron, Joseph
    Chen, Ying Q.
    Wang, Lei
    Ou, San-San
    Anderson, Maija
    McCauley, Marybeth
    Gamble, Theresa
    Kumarasamy, Nagalingeshwaran
    Hakim, James G.
    Kumwenda, Johnstone
    Pilotto, Jose H. S.
    Godbole, Sheela V.
    Chariyalertsak, Suwat
    de Melo, Marineide Goncalves
    Mayer, Kenneth H.
    Eshleman, Susan H.
    Piwowar-Manning, Estelle
    Makhema, Joseph
    Mills, Lisa A.
    Panchia, Ravindre
    Sanne, Ian
    Gallant, Joel
    Hoffman, Irving
    Taha, Taha E.
    Nielsen-Saines, Karin
    Celentano, David
    Essex, Max
    Havlir, Diane
    Cohen, Myron S.
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (04): : 281 - 290
  • [4] Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda (vol 16, pg 1391, 2002)
    Guay, LA
    Musoke, P
    Hom, DL
    Nakabiito, C
    Bagenda, D
    Fletcher, CV
    Marum, LH
    Fowler, MG
    Falksveden, LG
    Wahren, B
    Kataaha, P
    Wigzell, H
    Mmiro, FA
    Jackson, JB
    [J]. AIDS, 2002, 16 (14) : 1989 - 1989
  • [5] Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial (vol 399, pg 1790, 2022)
    Trutnovsky, G.
    Reich, O.
    Joura, E. A.
    [J]. LANCET, 2022, 400 (10359): : 1194 - 1194
  • [6] The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial (vol 4, pg e978, 2016)
    Pettifor, A.
    MacPhail, C.
    Hughes, J. P.
    [J]. LANCET GLOBAL HEALTH, 2017, 5 (02): : E146 - E146
  • [7] Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)
    Tolley, Elizabeth E.
    Li, Sue
    Zangeneh, Sahar Z.
    Atujuna, Millicent
    Musara, Petina
    Justman, Jessica
    Pathak, Subash
    Bekker, Linda-Gail
    Swaminathan, Shobha
    Stanton, Jill
    Farrior, Jennifer
    Sista, Nirupama
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 (10)
  • [8] Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study (vol 8, pg e185, 2021)
    Orkin, C.
    Oka, S.
    Philibert, P.
    [J]. LANCET HIV, 2021, 8 (12): : E734 - E734
  • [9] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (vol 399, pg 2113, 2022)
    Danese, S.
    Vermeire, S.
    Zhou, W.
    [J]. LANCET, 2022, 400 (10357): : 996 - 996
  • [10] Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples
    Safren, Steven A.
    Mayer, Kenneth H.
    Ou, San-San
    McCauley, Marybeth
    Grinsztejn, Beatriz
    Hosseinipour, Mina C.
    Kumarasamy, Nagalingeswaran
    Gamble, Theresa
    Hoffman, Irving
    Celentano, David
    Chen, Ying Qing
    Cohen, Myron S.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 69 (02) : 234 - 240